Slide 1: 3Q 2025 Financial Results
3Q 2025 Financial Results Nasdaq: NEO October 28, 2025
Slide 2: Safe Harbor Statements
Safe Harbor Statements This presentation has been prepared by NeoGenomics, Inc. (“we,” ”us,” “our,” “NeoGenomics” or the “Company”) and is made for informational purposes only and does not constitute an offer to sell or a solicitation of an offer to buy securities, nor shall there be any sale of any
Slide 3: Mission and Vision
Mission We save lives by improving patient care. Vision We are becoming the world’s leading provider of comprehensive cancer testing, data and solutions through uncompromising quality, exceptional customer experience, and innovative products and services.
Slide 4: Q3 Highlights: Delivering Results Across the Board
Q3 Highlights: Delivering Results Across the Board Strong clinical performance Strategic win NGS acceleration
Slide 5: 3rd Quarter Clinical Performance
3rd Quarter Clinical Performance Clinical Volume (unit thousands) Clinical Revenue per Test Clinical Revenue ($millions) 15% Reported 3% Reported 18% Reported 10% Same store 361 4% Same store $476 15% Same store $172 357 $164 $465 326 $463 322 $461 $150 $150 315 $459 $146 Q3'24 Q4'24 Q1'25 Q2'25 Q3'
Slide 6: 3rd Quarter Highlights
3rd Quarter Highlights Key Takeaways Clinical • Clinical Revenue grew 18% (15% Revenue excluding Pathline) Volume $188M | 12% growth • Clinical Volume grew at 15% and 10% 361K | 15% growth excluding Pathline • NGS revenue grew 24% over prior year • Adjusted EBITDA of $12M is the 9th Adj Gross Adj co
Slide 7: Affirming FY 2025 Guidance
Affirming FY 2025 Guidance Guidance as of July 29th, 2025 Guide ($ Millions) YoY% Growth Revenue $720 - $726 9 - 10 % Adj. EBIDTA $41 - $44 3 - 10 %
Slide 8: 3rd Quarter Financial Overview
3rd Quarter Financial Overview Financial Statement In $Millions 3Q’24 3Q’25 %vPY Revenue $167.8 $187.8 11.9% Adjusted Gross Profit $80.1 $85.4 6.6% Adjusted Gross Margin 47.8% 45.5% -228 bps Adjusted EBITDA $13.4 $12.2 -8.5% Adjusted EBITDA Margin 8.0% 6.5% -146 bps Cash and cash equivalents $361.9
Slide 9: Summary
Summary • Clinical momentum continued with 18% Revenue growth(15% on same store basis) • NGS Revenue grew 24% in the quarter and 22% YTD • AUP grew sequentially and increase over prior year driven by continued growth in higher valued tests and RCM initiatives • RaDaR Patent litigation victory • Laun
Slide 10: © 2024 NeoGenomics Laboratories, Inc. All rights reserved. All other trademarks are the property
© 2024 NeoGenomics Laboratories, Inc. All rights reserved. All other trademarks are the property of their respective owners. Rev. MMDDYY
Slide 11: Appendix
yas O c ® oe QO <x
Slide 12: Balance Sheet
September 30, 2025 (unaudited) December 31, 2024 ASSETS Current assets Cash and cash equivalents $ 164,117 $ 367,012 Balance Marketable securities, at fair value Accounts receivable, net — 155,296 19,832 150,540 Sheet Inventories 28,460 26,748 Prepaid assets 21,986 20,165 Other current assets 10,528
Slide 13: Income Statement
Three Months Ended September 30, Nine Months Ended September 30, 2025 2024 2025 2024 NET REVENUE $ 187,797 $ 167,824 $ 537,162 $ 488,566 Income COST OF REVENUE 107,351 92,944 306,212 275,723 Statement GROSS PROFIT Operating expenses: General and administrative 80,446 69,874 74,880 66,969 230,950 209
Slide 14: Statements of Cash Flows
Nine Months Ended September 30, 2025 2024 CASH FLOWS FROM OPERATING ACTIVITIES Net loss $ (98,144) $ (63,402) Statements of Adjustments to reconcile net loss to net cash used in operating activities: Depreciation 27,309 29,274 Cash Flows Amortization of intangibles 24,120 25,085 Stock-based compensa
Slide 15: Adjusted Gross Margin
Three Months Ended September 30, Nine Months Ended September 30, 2025 2024 % Change 2025 2024 % Change Adjusted Consolidated: Total revenue (GAAP) $ 187,797 $ 167,824 11.9 % $ 537,162 $ 488,566 9.9 % Gross Margin September 30, 2025 Cost of revenue (GAAP) Adjustments to cost of revenue(1) $ 107,351 (
Slide 16: Adjusted EBITDA
Three Months Ended September Nine Months Ended September 30, 30, 2025 2024 2025 2024 Adjusted Net loss (GAAP) Adjustments to net loss: $ (27,129) $ (17,699) $ (98,144) $ (63,402) EBITDA Interest income (1,563) (4,673) (7,547) (14,099) Interest expense 603 1,642 3,154 4,993 September 30, 2025 Income
Slide 17: Adjusted EBITDA 2025 Guidance
Year Ended December 31, 2025 Low Range High Range Net loss (GAAP) $ (116,000) $ (108,000) Adjusted Amortization of intangibles Stock-based compensation expenses 32,000 46,000 32,000 43,000 EBITDA Other one-time expenses 48,000 48,000 Adjusted net income (non-GAAP) 10,000 15,000 Interest and taxes (7